Portal de investigação
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial
Data de publicação:
Data Ahead of Print:
Unidades de investigação
Abstract
[No abstract available]
Dados da publicação
- ISSN/ISSNe:
- 0163-4453, 1532-2742
- Tipo:
- Letter
- Páginas:
- -
- Link para outro recurso:
- www.scopus.com
Journal of Infection W.B. Saunders Ltd
Citações Recebidas na Web of Science: 4
Citações Recebidas na Scopus: 5
Documentos
- Não há documentos
Filiações
Filiações não disponíveis
Keywords
- Antibodies, Monoclonal; Antibodies, Neutralizing; COVID-19; Drug Combinations; Humans; cilgavimab plus tixagevimab; placebo; remdesivir; cilgavimab; cilgavimab and tixagevimab drug combination; monoclonal antibody; neutralizing antibody; tixagevimab; cause of death; confidence interval; coronavirus disease 2019; drug safety; drug tolerability; follow up; hazard ratio; health care quality; health status; hospital patient; hospitalization; human; immune response; immunocompromised patient; immunology; Letter; mortality; oxygen supply; phase 3 clinical trial (topic); randomized controlled trial (topic); risk reduction; Severe acute respiratory syndrome coronavirus 2; unspecified side effect; vaccination; variant of concern; virus neutralization; virus resistance; virus strain; clinical trial; controlled study; coronavirus disease 2019; drug combination; phase 3 clinical trial; randomized controlled trial
Proyectos asociados
The impact of the Covid-19 pandemic on antimicrobial consumption: a descriptive and correlation analysis in a tertiary care hospital in Portugal
Investigador Principal: José Artur Osório de Carvalho Paiva
Estudo Clínico Académico (Antimicrobial consumpti) . 2021
Severe community-acquired pneumonia: from severity assessment to outcome.
Investigador Principal: José Artur Osório de Carvalho Paiva
Estudo Clínico Académico . 2022
Citar a publicação
Hites M,Lapique EL,Massonnaud CR,Belhadi D,Jamard S,Goehringer F,Danion F,Reignier J,de Castro N,Garot D,Lacombe K,Tolsma V,Faure E,Malvy D,Staub T,Courjon J,Cazenave F,Riise AMD,Leturnier P,Martin G,Roger C,Akinosoglou K,Le V,Piroth L,Sellier P,Lescure X,Troseid M,Clevenbergh P,Dalgard O,Gallien S,Gousseff M,Loubet P,Vardon F,Visee C,Belkhir L,Botelho E,Cabie A,Kotanidou A,Lanternier F,Rouveix E,Silva S,Thiery G,Poignard P,Carcelain G,Diallo A,Mercier N,Terzic V,Bouscambert M,Gaymard A,Trabaud M,Destras G,Josset L,Billard N,Thi H,Guedj J,Couffin S,Dechanet A,Delmas C,Esperou H,Fougerou C,Le S,Metois A,Noret M,Bally I,Dergan S,Tubiana S,Kalif O,Bergaud N,Leveau B,Eustace J,Greil R,Hajdu E,Halanova M,Paiva J,Piekarska A,Rodriguez J,Tonby K,Trojanek M,Tsiodras S,Unal S,Burdet C,Costagliola D,Yazdanpanah Y,Peiffer N,Mentre F,Ader F,DisCoVeRy GRP. Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial. J. Infect. 2024. 88(3):106120. IF:28,200. (1).
